

SMALL ANGLE NEUTRON SCATTERING (SANS): a complementary technique

Everything BioSAXS 9 – Advanced Topics – March 2, 2023

Susana Teixeira

Guest Researcher - NIST Center for Neutron Research
Gaithersburg MD, USA

susanat@udel.edu | scm5@nist.gov



UNIVERSITY OF DELAWARE
ENGINEERING

What is different about neutron scattering?

- Nature of the radiation used
- Incoherent Scattering
- Contrast


Notes on experimental planning & SAXS/SAS complementarity

- Sample volume/concentration
- Measuring match points
- Deuteration & HDX
- Where can I apply for beamtime?

Examples of applications


- Contrast variation studies
- Sample environment effects: pressure and temperature

See Differently With Neutrons at NIST



<https://www.nist.gov/video/see-differently-neutrons-nist>

Nature of the radiation used: neutrons



Real space

$$\vec{q} \equiv \vec{k}_i - \vec{k}_f$$

$$\Delta\omega \equiv E_i - E_f$$

Elastic scattering: $|k_i| = |k_f| = k = 2\pi/\lambda$

$$q = 2k \sin(\theta)$$

Reciprocal space

$$d \approx \frac{2\pi}{q}$$

$$q = \frac{4\pi}{\lambda} \sin(\theta)$$

Nature of the radiation used: neutrons


Neutrons have zero net charge.

Relatively low probability of interaction with nuclei:

- Neutrons are highly penetrating
- thicker materials can be probed
- samples in various containers can be probed (e.g. extreme environments)

Neutrons cause no radiation damage.

Neutron Wavelength:	10^{-10} m (Å)
Inter-atomic distances:	10^{-10} m (Å)
Atomic nuclei:	10^{-15} m (fm)
Strong nuclear forces:	10^{-15} m (fm)
Velocity of the neutrons:	10^{10} m.ps ⁻¹
Neutron flux at the sample position:	10^7 - 10^8 n.cm ⁻² s ⁻¹




[Neutrons have a magnetic moment and energies appropriate to study molecular vibrations, lattice excitations and dynamics of atomic motion]

Nature of the radiation used: neutrons

Incident Plane

Wave: e^{ikz}



$$\psi = -\frac{b}{r} e^{i\kappa \cdot r}$$

b: Scattering length of the nucleus (interaction between the neutron and the nucleus)

Probability of the interaction: b^2

Total Scattering cross section: $\sigma = \int \frac{d\sigma}{d\Omega} d\Omega = 4\pi|b|^2$

The concept of Incoherent Scattering

$$\sigma = \sigma_{coh}(q) + \sigma_{inc} + \sigma_{abs}$$

coherent:

depends on structure
q-dependent (S)



incoherent:

'noise' or 'background'
T-dependent (N)

absorption:

Reduces S/N
Wavelength dependent

$$I = I_0 \exp(-\mu d)$$



Data from the Special Feature section in *Neutron News*, Vol. 3, N. 3, 1992, pp. 29-37.

For elements or relatively simple molecules:

Scattering lengths (cm^{-1}) of elements:

<https://www.ncnr.nist.gov/resources/n-lengths/>

SLD (cm^{-2}) calculator:

<https://www.ncnr.nist.gov/resources/activation/>

Neutrons vs X-rays





Image adapted from: Fig. 22, Research (London) 7, 257 (1954)



X-rays

- High brilliance beams and larger cross sections
- Scattering length depends on atomic number and varies with q
- Light or similar Z elements are difficult to resolve
- keV energies

Neutrons

- Need more sample, longer exposures
- Depends on nuclei and no angular dependence
- light elements (H, D) have large cross sections; sensitive to different isotopes
- meV energies

Contrast

Fourier transform of the SLD distribution

$$I_{molecule}(q) \propto \frac{d\Sigma}{d\Omega}(q) = \frac{N}{V} \frac{d\sigma}{d\Omega}(q) = \frac{1}{V} \left| \int \rho(\mathbf{r}) e^{i\mathbf{q}\cdot\mathbf{r}} d\mathbf{r} \right|^2$$

Rayleigh-Gans Eq.

N atoms
occupying a volume V

We measure intensities

Macroscopic cross-section

We want to know the structure
[shape of the molecule, or F(q)]

$$\rho = \frac{\sum_i^N b_i}{V} = b_i \delta(\mathbf{r} - \mathbf{r}_i)$$

Molecule in solution

$$I_{molecule-solvent}(q) \propto \frac{1}{V} \left\langle \left| \int \Delta\rho e^{i\mathbf{q}\cdot\mathbf{r}} d\mathbf{r} \right|^2 \right\rangle$$





$$\overline{\Delta\rho} = \bar{\rho}_{mol} - \rho_{solv}$$

Generic plot: contrast variation and solvent matching

For N molecules with a density n (N/V), averaged over random orientations:


$$I(q) = n \Delta\rho^2 V^2 \langle |F(q)|^2 \rangle$$

Scattering length density (SLD) contrast



Deuteration: isotope labeling for higher or selective contrast

The **Biomolecular Labeling Laboratory (BL²)** is a joint NIST/UMD facility. The laboratory provides the infrastructure for labeling proteins, nucleotides and other biomolecules with stable isotopes so they can be used for structural and biophysical methods such as small angle neutron scattering (SANS). The BL² supports labeling of **proteins expressed in bacteria and yeast** and of **chemically synthesized peptides**.



Match point : experimental determination

$$I(q = 0) = n \Delta\rho^2 V^2 = \frac{C M_w}{N_A} \Delta\rho^2 v^2$$


C: concentration (g/cm³)

v: partial specific volume (cm³/g)

M_w: molar mass (g/mol)

$\Delta\rho$ varies with the % D₂O in the solvent

$$\sqrt{\frac{I(0)}{C}} \propto \Delta\rho^2 \propto f_{D_2O}$$



See (slide 14) for software to calculate contrast from sequence or PDB structures

Inhomogeneous SLD particles: beyond the Guinier approximation

Stuhrmann extended the Guinier approximation to account for the contrast dependence of the radius of gyration extracted from a fit to the scattering data. [Ibel, K. and Stuhrmann, H. B. (1975). J. Mol. Biol. 93, 255–265]

Stuhrman analysis

$$R_g^2 = R_0^2 + \frac{\alpha}{\Delta\rho} + \frac{\beta}{\Delta\rho^2}$$

Overall shape of the particle

R_0 : R_g of an equivalent homogeneous complex

Distribution of inhomogeneities

$$\alpha = \frac{1}{V} \int_r \rho_F(r) |r|^2 d^3r$$

$$\beta = \left(\frac{1}{V} \int_r \rho_F(r) |r| d^3r \right)^2$$

α : second moment of the internal density fluctuations within the scattering object:

- $\alpha = 0$ for a homogeneous scattering particle
- $\alpha > 0$ higher SLD towards the outside of the particle
- $\alpha < 0$ higher SLD towards the inside of the particle

β : Distance of the center of mass of the particle to the center of SLD of its heterogeneous components (if $\neq 0$ the centers of mass of the 2 components are not concentric)

Two component system with different SLD: Parallel-axis theorem

Relating the measured R_g to the distance D between the centers of SLD of each subunit [Moore, P. B. (1982). *Methods Exp. Phys.* 20, 337–390]:

$$R_g \text{ vs } \Delta\rho \quad R_g^2 = \frac{\Delta\rho_1 V_1}{\Delta\rho V} R_1^2 + \frac{\Delta\rho_2 V_2}{\Delta\rho V} R_2^2 + \frac{\Delta\rho_1 V_1 \Delta\rho_2 V_2}{(\Delta\rho V)^2} D^2$$




See **MULCh** (<http://www.mmb/usyd.edu.au/NCVWeb/>); *Rg module* analyses the contrast dependence of the radius of gyration to yield information relating to the size and disposition of the labelled and unlabeled components in a complex. The module *Compost* can also extract composite scattering profiles (essentially deconvoluting the data) for 2 component systems:

$$I(q) = \Delta\rho_1^2 I_1(q) + \Delta\rho_1 \Delta\rho_2 I_{12}(q) + \Delta\rho_2^2 I_2(q)$$

cross term

$$I_1(q = 0) = n \Delta\rho_1^2 V_1^2$$

volume of individual components can be determined for component 1 and 2



A contrast variation experiment

Calculations prior to the experiment:

- predict contrast values and match points based on chemical composition (primary structure, type of lipid, etc)
- Predict SANS curves at various contrasts if a low or high res model starting model is available

Experimental match point determination:

- determine the contrast match point of the complex and individual components

Stuhrmann Analysis and Parallel Axis Theorem

- Determine R_g for the individual components and the spatial relationship between the two components. Typically, 5 contrasts required.

Structure Modeling

- Model structures must fit data at all contrasts & SAXS data
- Use scattering from individual components as constraints if available.

Contrast variation software

MULCh: two component complexes

Rg, Contrast and compost modules

[Whitten et al. (2008), *J Appl Crystallogr* 41:222–226]

<http://smb-research.smb.usyd.edu.au/NCVWeb/>

SASSIE: (unlimited nr of components)

[Curtis, J.E., Raghunandan, S, Nanda, H. and Krueger, S. (2012), *Computer Physics Comm.* **183**, 382-389; Sarachan, K.L., Curtis, J.E. and Krueger S. (2013), *J. Appl. Crystallogr.* **46**, 1889-1893]

http://www.smallangles.net/sassie/SASSIE/SASSIE_HOME.html

<http://sassie-web.chem.utk.edu/sassie2/>

Contrast calculator: $I(0)$ analysis to plan experiments from sequence information or from coordinate (PDB) files.

SasCalc: Calculates theoretical SANS curves from all-atom structures taking contrast and H-D exchange into account.

A typical SANS experiment – Practical considerations

Typical sample volumes: 200-300 μL

For a labelled complex and a contrast variation experiment:

Concentrations ≥ 5 mg/mL

Total of 1-1.5 mL solution

Because of incoherent scattering:

- samples with more H_2O require higher exposure times for better statistics after solvent subtraction
- samples with less than 50% D_2O may need higher concentrations
- typical sample thickness 1 mm

Perform consistency checks before modeling:

- Is there a valid linear Guinier region ($qR_g < 1$)?
- Calculate the M_w from $I(0)$. Is it reasonable?
- Does R_g change with D_2O content of buffer*?

*Complementary SAXS measurements


Krueger, S. (2017). Designing and Performing Biological Solution Small-Angle Neutron Scattering Contrast Variation Experiments on Multi-component Assemblies. In: Chaudhuri, B., Muñoz, I., Qian, S., Urban, V. (eds)

Biological Small Angle Scattering: Techniques, Strategies and Tips. Advances in Experimental Medicine and Biology, vol 1009. Springer, Singapore.
https://doi.org/10.1007/978-981-10-6038-0_5

Example 1 – a contrast variation study | RSV Nanoparticle Vaccine: Protein-PS80 Complex


[Krueger S, Curtis J, Scott D, Grishaev A, Glenn G, Smith G, Ellingsworth L, Borisoz O, Maynard E (2021). *Mol. Pharm.* 18, 359-376]

Nanoparticles represent a powerful and versatile platform for development of vaccines to combat deadly pathogens such as respiratory syncytial virus (RSV), influenza, and recently, SARS-CoV-2.




Polysorbate 80 (PS80): $C_{64}H_{124}O_{26}$
Mw ~ 1310 Da

Prefusion RSV F



Postfusion RSV F




Prefusion and Postfusion RSV F trimer structures Mw ~ 180 kDa

Example 1 – a contrast variation study: why SANS?


[Krueger, S. et al., *Molecular Pharmaceutics* 18, 359-376 (2021)]

- Nanoparticle vaccine structures are challenging due to the heterogeneity of the membrane protein–detergent complex where the detergent mass may equal or exceed that of the protein.
- Atomistic structures are only partially available from X-ray crystallography, where the structure was manipulated to stabilize crystals
- TEM studies require extensive manipulation, including dilution prior to staining, drying and fixing on a grid: is the general morphology meaningful? **What is the stoichiometry and arrangement of the RSV trimers and PS80 in solution?**



Example 1 – RSV Nanoparticle Vaccine | SAXS and SANS data


[Krueger, S. et al., *Molecular Pharmaceutics* 18, 359-376 (2021)]



Monodispersity

(1) DLS/AUC

Particle size as a function of RSV F:PS80 ratio could be optimized for SAS studies.



Knowing your sample

(3) Phosphate Binding Assay

Indicated all PS80 was bound to RSV F with no free PS80 in solution.

Example 1 – SV Nanoparticle Vaccine: Protein-PS80 Complex | stoichiometry determination

[Krueger, S. et al., *Molecular Pharmaceutics* 18, 359-376 (2021)]

$$n = \frac{CMw_{total}}{N_A} \quad \text{where} \quad Mw_{total} = Mw_1 + Mw_2 \quad (\text{molar masses aka molecular weights})$$

At each contrast:

$$\frac{I(0)}{C} = \frac{Mw_{total}}{N_A} (f_1 \Delta\rho_1 \bar{v}_1 + f_2 \Delta\rho_2 \bar{v}_2)^2$$

where $f_1 = \frac{Mw_1}{Mw_1 + Mw_2}$
(mass fraction)

Knowns:

$\Delta\rho_1, \Delta\rho_2$: contrast for components 1 and 2



\bar{v}_1, \bar{v}_2 : partial specific volume for components 1 and 2

$I(0)$: measured $I(0)$ value

C : measured total concentration of the complex (protein + PS80)

Example 1 – SV Nanoparticle Vaccine| ensemble structure modeling

[Krueger, S. et al., *Molecular Pharmaceutics* 18, 359-376 (2021)]




Example 1 – a contrast variation study – ensemble structure modeling

[Krueger, S. et al., *Molecular Pharmaceutics* 18, 359-376 (2021)]


- The RSV F trimers exist as a distribution of prefusion and postfusion conformations and/or intermediate conformation(s), consistent with the broad immunogenic response elicited by the vaccine.

- The results suggest a mechanism of 1-D growth along the axis of the PS80 core with the ultimate size controlled by the RSV F:PS80 ratio.




Example 2 – Solvent matching: Biomineralization requires a delicate balance

See review: Lenton, S.; Wang, Q.; Nylander, T.; Teixeira, S.; Holt, C. *Crystals* 2020,10, 755.




Secreted Calcium Phosphate-binding Phosphoproteins (SCPPs) are involved in every aspect of Biomineralization. Examples:

- **Osteopontin (OPN)** ubiquitous in species, tissues and biofluids
- **Caseins** known to stabilize colloidal calcium phosphate in milk




Example 2 – Solvent matching: Biom mineralization and IDPs

Lenton S., Nylander T., Holt C., Sawyer L., Haertlein M., Mueller H., Teixeira S. (2016). *Eur Biophys J.* 45:405.



	<Core \emptyset >	<Shell>
OPN 1-149	≈ 35 nm	1.5 nm
β -casein 1-25	≈ 4.8 nm	1.6 nm
Biological apatite crystals:	few to hundreds of nm	
Posner Clusters:	0.9 nm	



There is a preponderance of IDPs in biocalcification due to several key properties:

A: packing advantages

B: higher density of PCs to modulate crystal nuclei growth

Example 2 – Solvent matching: Biom mineralization and IDPs

Before the experiment:

- predict contrast values and match points based on chemical composition (primary structure, calcium phosphate composition)
- test protein solubility and stability in D₂O buffers
- deuterate one of the components if necessary (use MS to determine final % deuteration)

Preliminary data:

- measure the match point of the protein
- ensure no effects from the use of D₂O (SAXS)

Why SANS was chosen:

- Non-destructive nature of neutrons allowed for repeat measurements of the same sample (with the same or complementary techniques)
- Natural contrast between complex components due to SLD difference
- No sample preparation artifacts: SANS is a non-invasive tool to investigate the structural properties and stability of multi-component complexes such as CPN

Example 3. mAb stability: what happens to proteins when we freeze them?

SUSTAINABILITY



Over 70% of Earth is under pressure.



Pressure increasingly used in Biopharma and Food processing

Maximally freeze concentrated solution ($T_g' \leq -35^\circ\text{C}$)





Image adapted from Hauptmann et al. (2019). *AAPS PharmSciTech* **20**: 72.

*Authelin et al. (2020). *J. Pharm. Sci.* **109**(1), 44.

Cryo-concentration, pH shifts, pressure, crystallization of excipients, ice/liquid interface

Monitoring vaccine wastage at country level. Immunization, Vaccines and Biologicals. WHO/V&B/03.18. Rev.1.

Example 3. mAb stability: pressure, low T and high T can denature a protein



$$\begin{aligned} \Delta G &= \Delta H - T\Delta S \\ &= \Delta U + P \cdot \Delta V - T\Delta S \end{aligned}$$








Image adapted from: Yang *et al* (2021). *J. Chem. Theory Comput.* 17, 515.

Example 3. Using High-pressure SANS to study mAb stability

Gomes D, Teixeira S, Leao J, Razinkov V, Qi W, Rodrigues M, Roberts C (2021). *Mol. Pharm.* **18**(12), 4415.



5 mg/mL AsIgG1, ≈ 150 kDa;

5 mM citrate buffer pD 4.0. $T_{CD} < -20$ °C; $pI \approx 8.6$



M. Rodrigues
(Lisbon)





D. Gomes
(Lisbon/Delaware)



C. Roberts
(Delaware)

Example 3. Using High-pressure SANS to study mAb stability


Gomes D, Teixeira S, Leao J, Razinkov V, Qi W, Rodrigues M, Roberts C (2021). *Mol. Pharm.* **18**(12), 4415.



T (°C)	ΔG _{un} (kJ/mol)	ΔV _{un} (mL/mol)	P _{1/2} (kbar)
50	14 (±2)	- 86 (±13)	1.59 (±0.05)
35	22 (±3)	- 89 (±13)	2.50 (±0.1)
-5	23 (±5)	- 135 (±30)	1.70 (±0.06)
-10	21 (±5)	- 144 (±37)	1.47 (±0.03)


Example 3. Using High-pressure SANS to study mAb stability

Gomes D, Teixeira S, Leao J, Razinkov V, Qi W, Rodrigues M, Roberts C (2021). *Mol. Pharm.* **18**(12), 4415.



Temperature: -20° to $+65^{\circ}\text{C}$
q-range: $0.001\text{-}0.3\text{ \AA}^{-1}$
Concentration: $>5\text{ mg/ml}$

<https://www.nist.gov/laboratories/tools-instruments/hp-biosans-lipss>




HP-SANS advantages:

- No radiation damage
- No protein size limitation
- Access to subzero T in the absence of ice
- Contrast variation

Disadvantages:

- larger sample volumes (2.5-5ml)
- slow throughput (use spectroscopies and HP-SAXS first when possible)



Berger et al. (2022). *J. Phys. Chem. B* 126, 24, 4431–4441

Conclusions & Where can I apply for beamtime

SANS experiments are low throughput (compared to SAXS) and may require isotope labeling (deuteration): SANS should only be used to provide information no other technique can access.

Typical applications of Bio-SANS:

- Rheology
- Studies at various T and P (e.g. freeze-thaw, lyophilization, accelerated degradation studies)
- Studies of Halophiles (high-salt)
- Contrast variation studies
- Studies of radiation-sensitive samples

SAXS and SANS are complementary techniques 😊

<https://www.ncnr.nist.gov/nsources.html>

North America

- NIST Center for Neutron Research
- Oak Ridge Neutron Facilities (SNS/HFIR)
- Los Alamos Neutron Science Center (LANSCE)
- University of Missouri Research Reactor Center
- Indiana University Cyclotron Facility

Acknowledgements



<https://www.nist.gov/ncnr/chrns/education-and-outreach>

SURF, CORE & Summer School
susanat@udel.edu | scm5@nist.gov



C. Gagnon
(UMD/NIST)



Z. Kelman
(UMD/NIST)



P. Butler
(NIST)



C. Roberts
(Delaware)



J. Leao
(NIST)



M. Rodrigues
(Lisbon)



J. Berger
(Delaware)



D. Gomes
(Lisbon/Delaware)



N. Wagner
(CNS, Delaware)



S. Krueger
(NIST)



Results presented were carried out under the cooperative agreement #70NANB20H133 from NIST, U.S. Department of Commerce. I acknowledge the support of the NIST in providing the neutron research facilities used, supported in part by the National Science Foundation under Agreement No. DMR-0944772. The statements, findings, conclusions and recommendations are those of the presenter and do not necessarily reflect the view of NIST or the U.S. Department of Commerce.